Carsten Müller-Tidow

Carsten Müller-Tidow

Auto-generated profile, based on publicly available information

Carsten Müller-Tidow

University Hospital Heidelberg, Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2023 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CSChristoph K. Stein-Thoeringer
Christoph K. Stein-Thoeringer
NSNeeraj Y. Saini
Neeraj Y. Saini
EZEli Zamir
Eli Zamir
VBViktoria Blumenberg
Viktoria Blumenberg
MSMaria-Luisa Schubert
Maria-Luisa Schubert
Eran ElinavEran Elinav
Eran Elinav

22 November 2021 in Nature Immunology
Verified
Journal Article
Open access
PDF file
SSSergio Heli Triana Sierra
Sergio Heli Triana Sierra
DVDominik Vonficht
Dominik Vonficht
LJLea Jopp-Saile
Lea Jopp-Saile
SRSimon Raffel
Simon Raffel
RLRaphael Lutz
Raphael Lutz
SHSimon Haas
Simon Haas
Single-cell genomics technology has transformed our understanding of complex cellular systems. However, excessive cost and a lack of strategies for the purification of newly identified cell types impede their functional characterization and large-scale profiling. Here, we have generated high-content single-cell proteo-genomic reference maps of human blood and bone marrow that quantitatively link the expression of up to 197 surface markers to cellular identities and biological processes across all main hematopoietic cell types in healthy aging and leukemia. These reference maps enable the automatic design of cost-effective high-throughput cytometry schemes that outperform state-of-the-art approaches, accurately reflect complex topologies of cellular systems and permit the purification of precisely defined cell states. The systematic integration of cytometry and proteo-genomic data enables the functional capacities of precisely mapped cell states to be measured at the single-cell level. Our study serves as an accessible resource and paves the way for a data-driven era in cytometry.

26 June 2017 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
FZFengbiao Zhou
Fengbiao Zhou
YLYi Liu
Yi Liu
CRChristian Rohde
Christian Rohde
CPCornelius Pauli
Cornelius Pauli
DGDennis Gerloff
Dennis Gerloff
CMCarsten Müller-Tidow
Carsten Müller-Tidow

15 June 2020 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
TRTobias Roider
Tobias Roider
JSJulian Seufert
Julian Seufert
AUAlexey Uvarovskii
Alexey Uvarovskii
FFFelix Frauhammer
Felix Frauhammer
MBMarie Bordas
Marie Bordas
SDSascha Dietrich
Sascha Dietrich
Tumour heterogeneity encompasses both the malignant cells and their microenvironment. While heterogeneity between individual patients is known to affect the efficacy of cancer therapy, most personalized treatment approaches do not account for intratumour heterogeneity. We addressed this issue by studying the heterogeneity of nodal B-cell lymphomas by single-cell RNA-sequencing and transcriptome-informed flow cytometry. We identified transcriptionally distinct malignant subpopulations and compared their drug-response and genomic profiles. Malignant subpopulations from the same patient responded strikingly differently to anti-cancer drugs ex vivo, which recapitulated subpopulation-specific drug sensitivity during in vivo treatment. Infiltrating T cells represented the majority of non-malignant cells, whose gene-expression signatures were similar across all donors, whereas the frequencies of T-cell subsets varied significantly between the donors. Our data provide insights into the heterogeneity of nodal B-cell lymphomas and highlight the relevance of intratumour heterogeneity for personalized cancer therapy.

2 February 2023 in Blood
Verified
Journal Article
Open access
PDF file
HMHideki Makishima
Hideki Makishima
RSRyunosuke Saiki
Ryunosuke Saiki
YNYasuhito Nannya
Yasuhito Nannya
SKSophia Claire Korotev
Sophia Claire Korotev
CGCarmelo Gurnari
Carmelo Gurnari
SOSeishi Ogawa
Seishi Ogawa
Germ line DDX41 variants have been implicated in late-onset myeloid neoplasms (MNs). Despite an increasing number of publications, many important features of DDX41-mutated MNs remain to be elucidated. Here we performed a comprehensive characterization of DDX41-mutated MNs, enrolling a total of 346 patients with DDX41 pathogenic/likely-pathogenic (P/LP) germ line variants and/or somatic mutations from 9082 MN patients, together with 525 first-degree relatives of DDX41-mutated and wild-type (WT) patients. P/LP DDX41 germ line variants explained ∼80% of known germ line predisposition to MNs in adults. These risk variants were 10-fold more enriched in Japanese MN cases (n = 4461) compared with the general population of Japan (n = 20 238). This enrichment of DDX41 risk alleles was much more prominent in male than female (20.7 vs 5.0). P/LP DDX41 variants conferred a large risk of developing MNs, which was negligible until 40 years of age but rapidly increased to 49% by 90 years of age. Patients with myelodysplastic syndromes (MDS) along with a DDX41-mutation rapidly progressed to acute myeloid leukemia (AML), which was however, confined to those having truncating variants. Comutation patterns at diagnosis and at progression to AML were substantially different between DDX41-mutated and WT cases, in which none of the comutations affected clinical outcomes. Even TP53 mutations made no exceptions and their dismal effect, including multihit allelic status, on survival was almost completely mitigated by the presence of DDX41 mutations. Finally, outcomes were not affected by the conventional risk stratifications including the revised/molecular International Prognostic Scoring System. Our findings establish that MDS with DDX41-mutation defines a unique subtype of MNs that is distinct from other MNs.

17 February 2025 in Nature
Verified
Journal Article
Open access
PDF file
VTVera Thiel
Vera Thiel
SRSimon Renders
Simon Renders
JPJasper Panten
Jasper Panten
NDNicolas Dross
Nicolas Dross
KBKatharina Bauer
Katharina Bauer
ATAndreas Trumpp
Andreas Trumpp
The peripheral nervous system (PNS) orchestrates organ function in health and disease. Most cancers, including pancreatic ductal adenocarcinoma (PDAC), are infiltrated by PNS neurons, and this contributes to the complex tumour microenvironment (TME)1,2. However, neuronal cell bodies reside in various PNS ganglia, far from the tumour mass. Thus, cancer-innervating or healthy-organ-innervating neurons are lacking in current tissue-sequencing datasets. To molecularly characterize pancreas- and PDAC-innervating neurons at single-cell resolution, we developed Trace-n-Seq. This method uses retrograde tracing of axons from tissues to their respective ganglia, followed by single-cell isolation and transcriptomic analysis. By characterizing more than 5,000 individual sympathetic and sensory neurons, with about 4,000 innervating PDAC or healthy pancreas, we reveal novel neuronal cell types and molecular networks that are distinct to the pancreas, pancreatitis, PDAC or melanoma metastasis. We integrate single-cell datasets of innervating neurons and the TME to establish a neuron–cancer–microenvironment interactome, delineate cancer-driven neuronal reprogramming and generate a pancreatic-cancer nerve signature. Pharmacological denervation induces a pro-inflammatory TME and increases the effectiveness of immune-checkpoint inhibitors. The taxane nab-paclitaxel causes intratumoral neuropathy, which attenuates PDAC growth and, in combination with sympathetic denervation, results in synergistic tumour regression. Our multi-dimensional data provide insights into the networks and functions of PDAC-innervating neurons, and support the inclusion of denervation in future therapies.